Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Namzaric Generic Name & Formulations
Legal Class
Rx
General Description
Memantine HCl extended-release, donepezil HCl; 7mg/10mg, 14mg/10mg, 21mg/10mg, 28mg/10mg; caps.
Pharmacological Class
NMDA receptor antagonist + acetylcholinesterase inhibitor.
How Supplied
Caps 7mg/10mg, 21mg/10mg—30; 14mg/10mg, 28mg/10mg—30, 90
Manufacturer
Generic Availability
NO
Namzaric Indications
Indications
Moderate-to-severe dementia of the Alzheimer's type in patients stabilized on 10mg of donepezil HCl once daily.
Namzaric Dosage and Administration
Adult
Swallow whole or may open caps and sprinkle on applesauce, then consume entire contents; do not divide doses. Patients stabilized on donepezil HCl 10mg: initially 7mg/10mg once daily in the PM; increase at minimum weekly intervals in 7mg increments of memantine HCl to max maintenance dose of 28mg/10mg once daily; severe renal impairment (CrCl 5–29mL/min): initially 7mg/10mg once daily in the PM; increase to maintenance dose of 14mg/10mg once daily after one week. Patients stabilized on both components: 28mg/10mg once daily in the PM. Start the day after last dose of memantine HCl and donepezil HCl given separately. Severe renal impairment (CrCl 5–29mL/min): 14mg/10mg once daily.
Children
Not established.
Namzaric Contraindications
Not Applicable
Namzaric Boxed Warnings
Not Applicable
Namzaric Warnings/Precautions
Warnings/Precautions
Cardiac conduction abnormalities. Peptic ulcer. Monitor for GI bleeding. GU obstruction. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine levels. Seizures. Asthma or COPD. Severe hepatic impairment. Pregnancy. Nursing mothers.
Namzaric Pharmacokinetics
Elimination
Renal. Half-life: 60–80 hours (memantine); ~70 hours (donepezil).
Namzaric Interactions
Interactions
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). Memantine plasma levels may be increased by urinary alkalinizers. Donepezil potentiated by CYP3A4 (eg, ketoconazole) and CYP2D6 (eg, quinidine) inhibitors. CYP3A4 inducers (eg, phenytoin, carbamazepine, dexamethasone, rifampin, phenobarbital) may increase the rate of elimination of donepezil. Antagonizes anticholinergics. Additive effects with succinylcholine-type muscle relaxants (during anesthesia), other cholinesterase inhibitors, cholinergic agonists (eg, bethanechol). Concomitant NSAIDs may increase risk of GI bleed.
Namzaric Adverse Reactions
Adverse Reactions
Headache, diarrhea, dizziness, anorexia, vomiting, nausea, ecchymosis.
Namzaric Clinical Trials
See Literature
Namzaric Note
Not Applicable
Namzaric Patient Counseling
See Literature
